Mammogen Raises Up to $30M for RNA Blood Test That Could Reduce Unnecessary Breast Biopsies
11 June 2026
Femtech Insider featured Mammogen following the company’s Series A financing of up to $30 million to advance genTRU-breast™, its RNA-powered blood test designed to support earlier breast cancer detection in women with dense breast tissue.
The article explores how genTRU-breast is being developed as a triage tool following mammography, with the potential to help women and their physicians make more informed decisions about supplemental imaging and biopsy.
The coverage also highlights Mammogen’s clinical progress, including its ongoing pivotal study, and features insights from CEO Elizabeth Cormier-May on the impact earlier detection can have on treatment options.
NBC 10 News featured Mammogen CEO Elizabeth Cormier-May in its coverage of the evolving landscape of blood-based cancer detection and an upcoming FDA advisory committee review of GRAIL’s Galleri test. Cormier-May shared her perspective on the significance of liquid biopsy technology and discussed how Mammogen’s approach differs by focusing specifically on earlier breast cancer detection. The story also highlights Mammogen’s blood-based test and its potential role in supporting women who may need additional testing following their annual mammogram. Read the full article on NBC 10 News →
The Scientist | Elizabeth Cormier-May In this contributed article for The Scientist, Mammogen Co-Founder and CEO Elizabeth Cormier-May explores why RNA may represent the next frontier in molecular diagnostics. The article examines how RNA can provide a dynamic view of what is happening biologically in real time, and why that information may be particularly valuable in early cancer detection. Cormier-May also discusses the importance of moving beyond simply detecting disease earlier toward generating insights that can meaningfully inform clinical decisions and patient care. Read the full article on The Scientist →
RNA opens a window into biology in motion, shifting molecular diagnostics from measuring more biology to finding the right biology in time to change patient care.